Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-dependent manner

Immunology and Cell Biology

Volumn 88, Issue 2, 2010, Pages 228-232

  Logan, Grant J ^a   Wang, Lina ^b   Zheng, Maolin ^a   Coppel, Ross L ^b   Alexander, Ian E ^a,c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adeno associated virus; C3d; Genetic adjuvants; Genetic vaccine; Molecular adjuvants

Indexed keywords

ANTIBODY; ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D1; COMPLEMENT COMPONENT C3D2; COMPLEMENT COMPONENT C3D3; COMPLEMENT COMPONENT C3D4; LYSOZYME; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; PARASITE ANTIGEN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VACCINE; DNA VACCINE; HYBRID PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG PACKAGING; EGG; FEMALE; GENETIC IMMUNIZATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PARVOVIRUS; PLASMODIUM YOELII; SIGNAL TRANSDUCTION; TANDEM REPEAT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; ANIMAL; ANTIBODY PRODUCTION; CELL LINE; GENE VECTOR; GENETICS; IMMUNOLOGY; TITRIMETRY;

ADENO-ASSOCIATED VIRUS; PLASMODIUM YOELII;

ANIMALS; ANTIBODY FORMATION; ANTIGENS; CELL LINE; COMPLEMENT C3D; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; IMMUNITY, HUMORAL; MICE; RECOMBINANT FUSION PROTEINS; TITRIMETRY; TRANSGENES; VACCINES, DNA; VIRAL VACCINES;

EID: 77149147762     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.92     Document Type: Article

References (42)

1. Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28: 1089-1103.
2. Xin KQ, Hamajima K, Sasaki S, Honsho A, Tsuji T, Ishii N et al. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1. Immunology 1998; 94: 438-444.
3. Kim JJ, Yang JS, Dentchev T, Dang K, Weiner DB. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 2000; 20: 487-498.
4. Davis WC, Konzek RL, Haas K, Estes DM, Hamilton MJ, Call DR et al. Use of the mannan receptor to selectively target vaccine antigens for processing and antigen presentation through the MHC class I and class II pathways. Ann NY Acad Sci 2002; 969: 119-125.
5. Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci USA 2007; 104: 1289-1294.
6. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998; 392: 408-411.
7. Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106: 1278-1285.
8. Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15: 641-646.
9. Nielsen CH, Fischer EM, Leslie RG. The role of complement in the acquired immune response. Immunology 2000; 100: 4-12.
10. Roozendaal R, Carroll MC. Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 2007; 219: 157-166.
11. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271: 348-350.
12. Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000; 1: 127-131.
13. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 2001; 17: 829-835.
14. Green TD, Montefiori DC, Ross TM. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 2003; 77: 2046-2055.
15. Green TD, Newton BR, Rota PA, Xu Y, Robinson HL, Ross TM. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 2001; 20: 242-248.
16. Tong T, Fan H, Tan Y, Xiao S, Ling J, Chen H et al. C3d enhanced DNA vaccination induced humoral immune response to glycoprotein C of pseudorabies virus. Biochem Biophys Res Commun 2006; 347: 845-851.
17. Xin KQ, Urabe M, Yang J, Nomiyama K, Mizukami H, Hamajima K et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 2001; 12: 1047-1061.
18. Gallez-Hawkins G, Li X, Franck AE, Thao L, Lacey SF, Diamond DJ et al. DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine 2004; 23: 819-826.
19. Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005; 79: 955-965.
20. Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine 2008; 26: 1644-1651.
21. Lin J, Zhi Y, Mays L, Wilson JM. Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J Virol 2007; 81: 11840-11849.
22. Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest 2007; 117: 3958-3970.
23. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X et al. Recombinant adenoassociated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000; 74: 2888-2894.
24. Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C et al. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum Gene Ther 2004; 15: 856-864.
25. Han G, Li Y, Wang J, Wang R, Chen G, Song L et al. Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD(500-585). J Immunol 2005; 174: 4516-4524.
26. Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 2003; 14: 365-379.
27. During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000; 287: 1453-1460.
28. Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel RL, Alexander IE. AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. Vaccine 2007; 25: 1014-1022.
29. Logan GJ, Wang L, Zheng M, Ginn SL, Coppel RL, Alexander IE. Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules. Gene Therapy 2009; 16: 200-210.
30. Carter RH, Spycher MO, Ng YC, Hoffman R, Fearon DT. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol 1988; 141: 457-463.
31. Chakravarty L, Zabel MD, Weis JJ, Weis JH. Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation. Int Immunol 2002; 14: 139-146.
32. Suradhat S, Braun RP, Lewis PJ, Babiuk LA, van Drunen Littel-van den Hurk S, Griebel PJ et al. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet Immunol Immunopathol 2001; 83: 79-92.
33. Gor DO, Ding X, Li Q, Greenspan NS. Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. Immunol Lett 2006; 102: 38-49.
34. Lee Y, Haas KM, Gor DO, Ding X, Karp DR, Greenspan NS et al. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J Immunol 2005; 175: 8011-8023.
35. Guan QD, Wang Y, Chu YW, Wang LX, Ni J, Guo Q et al. The distinct effects of three tandem repeats of C3d in the immune responses against tumor-associated antigen hCGbeta by DNA immunization. Cancer Immunol Immunother 2007; 56: 875-884.
36. Bergmann-Leitner ES, Scheiblhofer S, Weiss R, Duncan EH, Leitner WW, Chen D et al. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int Immunol 2005; 17: 245-255.
37. Bergmann-Leitner ES, Leitner WW, Tsokos GC. Complement 3d: from molecular adjuvant to target of immune escape mechanisms. Clin Immunol 2006; 121: 177-185.
38. Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E et al. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine 2007; 25: 7732-7736.
39. Kedzierski L, Black CG, Coppel RL. Characterization of the merozoite surface protein 4/ 5 gene of Plasmodium berghei and Plasmodium yoelii. Mol Biochem Parasitol 2000; 105: 137-147.
40. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
41. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A 'humanized' green fluorescent protein cDNA adapted for high- level expression in mammalian cells. J Virol 1996; 70: 4646-4654.
42. Kedzierski L, Black CG, Stowers AW, Goschnick MW, Kaslow DC, Coppel RL. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii. Vaccine 2001; 19: 4661-4668.